Verinata Health, Inc. Peer-Reviewed Publication Shows Circulating Cell-Free Fetal DNA Fractions Differ in Specific Aneuploidies
Published: Sep 19, 2013
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced Verinata Health, an Illumina company, published additional peer-reviewed data1 showing that Verinata’s non-invasive verifi® prenatal test2 correctly detects aneuploidies across all test samples, even for patients with very low fetal fractions (cell-free DNA fragments in maternal blood contributed from the fetus). The publication also documented that fetal fractions are different for pregnancies where the fetus has Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and other aneuploidies analyzed by the verifi® prenatal test.
Help employers find you! Check out all the jobs and post your resume.